Gilead wins ap­proval for long-act­ing HIV in­jec­tion af­ter re­solv­ing vial con­cerns

Gilead fi­nal­ly gained FDA ap­proval on Thurs­day for lenaca­pavir, its close­ly-watched cap­sid in­hibitor for HIV-1, the most com­mon type of HIV.

Lenaca­pavir will be mar­ket­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER